Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
AtriCure: Promising Cardiovascular Surgical Platform
AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago.
AtriCure Q2 Earnings Call Highlights
AtriCure NASDAQ: ATRC reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management, appendage management and open ablation franchises while noting continued pressure in minimally invasive ablation.
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Do Options Traders Know Something About AtriCure Stock We Don't?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
AtriCure NASDAQ: ATRC executives said the company's 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding opportunities in pain management and appendage management.
